Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine HCl for Post-operative Pain Control in Cutaneous Surgery
NCT04260854Phase 1Enrolling by invitation
- Sponsor
- Northwestern University
- Start
- Jan 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of bupivacaine hydrochloride 0.75% injection in postoperative pain (2 arms), sponsored by Northwestern University. Primary endpoint: Reported opioid and non-opioid pain medications taken at 3 days. Started Jan 2024; status: enrolling by invitation.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04260854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260854.